

Skin Disease-Oriented Team

Clinical Research Treatment Flowchart

Clinical Research Manager:
Mehir Tharani

Clinical Research Coordinators:
Bao-An Huynh
Natalie Arechiga
Erin Palmer-Torrison
Anastasiia Reipolska

First Line, Resectable

SWOG 2015
 1cm v 2cm margin
 PI: Yamamoto
 CRC: N. Arechiga
 Accrual: 13/30

Adjuvant, Stage 2

UCI 23-220
 Pembro vs Biosimilar
 PI: Chow
 CRC: E. Palmer-Torrison
 Accrual: 0/10
Pending Activation

**First Line, Stage 3
 Neoadjuvant + Adjuvant**

EA6194
 TLR9 agonist+Pembro + Sx
 vs Pembro + Sx
 PI: Tran
 CRC: E. Palmer-Torrison
 Accrual: 3/5
Suspended

UCI 23-220
 Adjuvant Pembro vs
 Biosimilar
 PI: Chow
 CRC: E. Palmer-Torrison
 Accrual: 0/10
Pending Activation

**First Line, Metastatic or
 unresectable without previous
 CPI**

EA6141
(III or IV)
 Ipi + Nivo + sargramostin **vs.**
 Ipi + Nivo
 PI: Chow
 CRC: B. Huynh
 Accrual: 4/7

**2nd Line +
 Metastatic or unresectable**

UCI 24-82
 MEK/RAF Inhibitors
 (RAS/RAF mutation
 NRAS or BRAF class II or III)
 PI: Valerin
 CRC: TBD
 Accrual: 0/10

UCI 22-49
 Pembro + Cyclophosphamide
 PI: Chow
 CRC: TBD
 Accrual: 0/10
Pending Activation

UCI 24-112
 Vusolimogene Oderparepvec
 (HSV-1) + Nivo **vs.**
 Physician's Choice
 PI: Tran
 CRC: TBD
 Accrual: 0/5
Pending Activation

Open

Low Accrual

Pending
 Activation
 or
 Suspended

Consider Broad Phase 1 Studies

UCI 20-67

DF1001 (HER2 NK- engager)
PI: Valerin
CRC: M. Nguyen
Accrual: 18/20

UCI 21-40

DF6002 (IL-12)
monotherapy and combo
(Nivolumab)
PI: Valerin
CRC: B. Huynh
Accrual: 5/10

UCI 23-197

DF6215 (IL-2)
PI: Valerin
CRC: N. Arechiga
Accrual: 1/5
Waitlist only

UCI 22-156

PI: Parajuli
Mechanism: TIL
Coordinator: J. Miranda
Accrual: 0/5
**Slot request to sponsor
for availability**

UCI 24-82

MEK/RAF Inhibitors
(RAS/RAF mutation
NRAS or BRAF class II or III)
PI: Valerin
CRC: TBD
Accrual: 0/10

Open

Low Accrual

Pending
Activation
or
Suspended

Non-interventional Trials

UCI 19-135
DecisionDx-Melanoma Impact on
Sentinel Lymph Node Biopsy Decisions
and Clinical Outcomes (DECIDE)
PI: Yamamoto
CRC: Anastasiia R.
Accrual: 84/90

UCI 23-149
Multiphoton Microscopy Imaging as a
Tool to Monitor Immune Activation
Induced by Checkpoint Inhibitors
PI: Ganesan
CRC: TBD.
Accrual: 2/15

UCI 23-93
Assessment of ICOS as a Novel Biomarker
to Determine Response and Resistance of
Checkpoint Immunotherapy for Cutaneous
Malignancies
PI: Tran
CRC: TBD
Target Accrual: 15
Pending Activation

Open

Low Accrual

Pending
Activation
or
Suspended

Recurrent

ETCTN 10592

M1774 +/- avelumab

PI: Gao

CRC: N. Arechiga

Accrual: 1/6

Open

Low Accrual

Pending
Activation
or
Suspended

Broad Phase 1 trials

UCI 21-40

DF6002 (IL-12)
monotherapy and combo
(Nivolumab)

PI: Valerin

CRC: B. Huynh

Accrual: 5/10

Open

Low Accrual

Pending
Activation
or
Suspended

Non-interventional Trials

UCI 11-30

(IRB 2008-6307)

Skin Imaging with Technologies in Development

PI: Kelly

Accrual: 632/750

UCI 13-13

(IRB 2011-8494)

In-Vivo Non-Invasive Skin Imaging Using
Multiphoton Microscopy and Multispectral Imaging

PI: Kelly

Accrual: 202/250

Interventional Trials

UCI 23-153

Topical HT-001 for Skin Toxicities w/EGFR Inhib.

PI: Smith

CRC: B. Huynh

Accrual: 0/6

Open

Low Accrual

Pending
Activation
or
Suspended